Reuters logo
BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA
May 1, 2017 / 12:59 PM / 7 months ago

BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA

May 1 (Reuters) - TESARO Inc-

* TESARO announces submission of investigational new drug application for anti-lag antibody tsr-033 to the u.s. Fda

* A phase 1 clinical study of tsr-033 is planned to begin in mid-2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below